Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;52(7):1466-1475.
doi: 10.18502/ijph.v52i7.13248.

Risk Factors for Potential Drug-Drug Interactions in Outpatients with Dyslipidemia

Affiliations

Risk Factors for Potential Drug-Drug Interactions in Outpatients with Dyslipidemia

Ninoslava Lalatović et al. Iran J Public Health. 2023 Jul.

Abstract

Background: Patients with dyslipidemia are usually multimorbid and require polypharmacy. Therefore, it is important to identify potential drug-drug interactions (pDDIs) in time to prevent their consequences. We aimed to identify and analyze risk factors contributing to their occurrence to guide health professionals.

Methods: A prospective cross-sectional study of 216 outpatients with dyslipidemia was conducted from May 2021 to April 2022 in Podgorica, the capital of Montenegro. pDDIs were identified using Medscape, Epocrates, and Drugs online interaction checkers. Multivariate regression analysis was performed to evaluate the potential predictors of interactions.

Results: pDDIs were detected in 212 (98.1%) participants, whereas pDDIs with high clinical significance were detected in 25.46%, 40.74%, and 58.8% of subjects by Drugs, Epocrates, and Medscape, respectively. Polypharmacy emerged as a risk factor for the occurrence of pDDIs in all three checkers in each category of clinical significance. The use of non-steroidal anti-inflammatory drugs and antiplatelet drugs contributes to the incidence of severe pDDIs B=1.014, 95%CI 0.681-1.346, P=0.000 and B=0.492, 95%CI 0.286-0.698, P=0.000, by Epocrates and Medscape respectively. The number of prescribers per patient was a protective factor against moderate pDDI B= -0.858, 95%CI -1.572-(-0.144), P=0.019 and B= -0.956, 95%CI -1.671-(-0.241), P=0.009, by Medscape and Epocrates, respectively, but a risk factor for the occurrence of minor pDDIs B=0.373, 95%CI 0.033-0.712 P=0.032 and B=0.143, 95%CI 0.042-0.244, P=0.006, by the same checkers.

Conclusion: Knowledge of the risk factors contributing to the occurrence of pDDIs is important for the development and implementation of strategies for their prevention, and given the high prevalence of dyslipidemia, understanding these factors seems crucial nowadays.

Keywords: Drug-drug interactions; Dyslipidemia; Interaction checker; Risk factors.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest The authors declare that there is no conflict of interests.

Similar articles

References

    1. Kopin L, Lowenstein CJ. (2017). Dyslipidemia. Ann Intern Med, 167(11):ITC81–ITC96. - PubMed
    1. Liu G, Shepherd J, Rane P, et al. (2019). Characteristics of patients with dyslipidemia treated in routine care setting in China. J Drug Assess, 8(1):192–8. - PMC - PubMed
    1. Mach F, Baigent C, Catapano AL, et al. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 41(1):111–88. - PubMed
    1. Stafford G, Villén N, Roso-Llorach A, Troncoso-Mariño A, Monteagudo M, Violán C. (2021). Combined multimorbidity and polypharmacy patterns in the elderly: A cross-sectional study in primary health care. Int J Environ Res Public Health, 18(17):9216. - PMC - PubMed
    1. Johnell K, Klarin I. (2007). The Relationship between Number of Drugs and Potential Drug-Drug Interactions in the Elderly A Study of Over 600 000 Elderly Patients from the Swedish Prescribed Drug Register. Drug Saf, 30(10):911–8. - PubMed

LinkOut - more resources